These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 25130477)

  • 41. Using Informatics Tools to Identify Opportunities for Precision Medicine in Diffuse Large B-cell Lymphoma.
    Patel SP; Harkins RA; Lee MJ; Flowers CR; Koff JL
    Clin Lymphoma Myeloma Leuk; 2020 Apr; 20(4):234-243.e10. PubMed ID: 32063526
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Next-Generation Sequencing Highlights of Diffuse Large B-cell Lymphoma in a Tertiary Care Hospital in North India.
    Mamgain G; Naithani M; Patra P; Mamgain M; Morang S; Nayak J; Kumar K; Singh S; Bakliwal A; Rajoreya A; Vaniyath S; Chattopadhyay D; Chetia R; Gupta A; Dhingra G; Sundriyal D; Nath UK
    Cureus; 2022 Aug; 14(8):e28241. PubMed ID: 36158348
    [TBL] [Abstract][Full Text] [Related]  

  • 43. TP53 dysfunction in diffuse large B-cell lymphoma.
    Lu TX; Young KH; Xu W; Li JY
    Crit Rev Oncol Hematol; 2016 Jan; 97():47-55. PubMed ID: 26315382
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas.
    Naylor TL; Tang H; Ratsch BA; Enns A; Loo A; Chen L; Lenz P; Waters NJ; Schuler W; Dörken B; Yao YM; Warmuth M; Lenz G; Stegmeier F
    Cancer Res; 2011 Apr; 71(7):2643-53. PubMed ID: 21324920
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Loss of B-cell receptor expression defines a subset of diffuse large B-cell lymphoma characterized by silent BCR/PI3K/AKT signaling and a germinal center phenotype displaying low-risk clinicopathologic features.
    Wang WG; Cui WL; Wang L; Zhu F; Wan XC; Ping B; Zhou XY; Li XQ
    Am J Surg Pathol; 2015 Jul; 39(7):902-11. PubMed ID: 25970684
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell Lymphomas.
    Morin RD; Assouline S; Alcaide M; Mohajeri A; Johnston RL; Chong L; Grewal J; Yu S; Fornika D; Bushell K; Nielsen TH; Petrogiannis-Haliotis T; Crump M; Tosikyan A; Grande BM; MacDonald D; Rousseau C; Bayat M; Sesques P; Froment R; Albuquerque M; Monczak Y; Oros KK; Greenwood C; Riazalhosseini Y; Arseneault M; Camlioglu E; Constantin A; Pan-Hammarstrom Q; Peng R; Mann KK; Johnson NA
    Clin Cancer Res; 2016 May; 22(9):2290-300. PubMed ID: 26647218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Mutations of CARD11 but not TNFAIP3 may activate the NF-kappaB pathway in primary CNS lymphoma.
    Montesinos-Rongen M; Schmitz R; Brunn A; Gesk S; Richter J; Hong K; Wiestler OD; Siebert R; Küppers R; Deckert M
    Acta Neuropathol; 2010 Oct; 120(4):529-35. PubMed ID: 20544211
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma.
    Pham LV; Bryant JL; Mendez R; Chen J; Tamayo AT; Xu-Monette ZY; Young KH; Manyam GC; Yang D; Medeiros LJ; Ford RJ
    Oncotarget; 2016 Dec; 7(49):80599-80611. PubMed ID: 27716624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Whole-exome and transcriptome sequencing of refractory diffuse large B-cell lymphoma.
    Park HY; Lee SB; Yoo HY; Kim SJ; Kim WS; Kim JI; Ko YH
    Oncotarget; 2016 Dec; 7(52):86433-86445. PubMed ID: 27835906
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas.
    Braggio E; Van Wier S; Ojha J; McPhail E; Asmann YW; Egan J; da Silva JA; Schiff D; Lopes MB; Decker PA; Valdez R; Tibes R; Eckloff B; Witzig TE; Stewart AK; Fonseca R; O'Neill BP
    Clin Cancer Res; 2015 Sep; 21(17):3986-94. PubMed ID: 25991819
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diffuse large B-cell lymphomas of immunoblastic type are a major reservoir for MYC-IGH translocations.
    Horn H; Staiger AM; Vöhringer M; Hay U; Campo E; Rosenwald A; Ott G; Ott MM
    Am J Surg Pathol; 2015 Jan; 39(1):61-6. PubMed ID: 25229766
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Advances in the molecular diagnosis of diffuse large B-cell lymphoma in the era of precision medicine.
    Araf S; Korfi K; Rahim T; Davies A; Fitzgibbon J
    Expert Rev Mol Diagn; 2016 Oct; 16(10):1093-1102. PubMed ID: 27648481
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Driving toward precision medicine for B cell lymphomas: Targeting the molecular pathogenesis at the gene level.
    Chung C
    J Oncol Pharm Pract; 2020 Jun; 26(4):943-966. PubMed ID: 31964218
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunohistochemical and genomic profiles of diffuse large B-cell lymphomas: implications for targeted EZH2 inhibitor therapy?
    Dubois S; Mareschal S; Picquenot JM; Viailly PJ; Bohers E; Cornic M; Bertrand P; Veresezan EL; Ruminy P; Maingonnat C; Marchand V; Lanic H; Penther D; Bastard C; Tilly H; Jardin F
    Oncotarget; 2015 Jun; 6(18):16712-24. PubMed ID: 25762637
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Mutations within the 5' region of FAS/CD95 gene in nodal diffuse large B-cell lymphoma.
    Scholl V; Stefanoff CG; Hassan R; Spector N; Renault IZ
    Leuk Lymphoma; 2007 May; 48(5):957-63. PubMed ID: 17487740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Precision Medicine for Diffuse Large B-cell Lymphoma.
    Lim MS; Elenitoba-Johnson KS
    Clin Cancer Res; 2016 Jun; 22(12):2829-31. PubMed ID: 26988247
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Common and HIV-related diffuse large B-cell lymphomas differ in their immunoglobulin gene mutation pattern.
    Delecluse HJ; Hummel M; Marafioti T; Anagnostopoulos I; Stein H
    J Pathol; 1999 Jun; 188(2):133-8. PubMed ID: 10398155
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Signal Pathways and Therapeutic Prospects of Diffuse Large B Cell Lymphoma.
    Sun F; Fang X; Wang X
    Anticancer Agents Med Chem; 2019; 19(17):2047-2059. PubMed ID: 32009599
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Genetic aberrations of signaling pathways in lymphomagenesis: revelations from next generation sequencing studies.
    Rossi D; Ciardullo C; Gaidano G
    Semin Cancer Biol; 2013 Dec; 23(6):422-30. PubMed ID: 23665546
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.